Vasorelaxation induced by prostaglandin E 2 in human pulmonary vein: Role of the EP 4 receptor subtype

British Journal of Pharmacology

Volumn 154, Issue 8, 2008, Pages 1631-1639

  Foudi, N ^a,b   Kotelevets, L ^c   Louedec, L ^a   Leseche G ^d   Henin, D ^d   Chastre, E ^c   Norel, X ^a,d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^d BICHAT HOSPITAL   (France)

Author keywords

EP2 receptor; EP4 receptor; Human pulmonary artery; Human pulmonary vein; Prostaglandin E2; Vasorelaxation

Indexed keywords

(4,5 DIHYDRO 1H IMIDAZOL 2 YL)[4 (4 ISOPROPOXYBENZYL)PHENYL]AMINE; 16 (3 METHOXYMETHYL)PHENYL OMEGA TETRANOR 3,7 DITHIAPROSTAGLANDIN E; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; 9 DEOXY 9BETA CHLORO 15 DEOXY 16 HYDROXY 17,17 TRIMETHYLENE 19,20 DIDEHYDROPROSTAGLANDIN E2; CAY 10441; GW 627368X; INDOMETACIN; L 877499; L 902688; MESSENGER RNA; N [2 [4 (4,9 DIETHOXY 1 OXO 1,3 DIHYDRO 2H BENZO[F]ISOINDOL 2 YL)PHENYL]ACETYL]BENZENESULFONAMIDE; N(G) NITROARGININE; NORADRENALIN; ONO 8713; ONO AE1 329; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN E2 DERIVATIVE; PROSTAGLANDIN E4 RECEPTOR; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTANOID RECEPTOR; RAMATROBAN; RECEPTOR SUBTYPE; SC 51 322; SC 51322;

ADULT; AGED; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MALE; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY VEIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; VASODILATATION;

AGED; DINOPROSTONE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MYOCYTES, SMOOTH MUSCLE; PULMONARY ARTERY; PULMONARY VEINS; RECEPTORS, PROSTAGLANDIN E; VASODILATION;

EID: 49449107477     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.214     Document Type: Article

References (44)

1. Abramovitz M, Adam M, Boie Y, Carriere M, Denis D, Godbout C et al. (2000). The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 1483: 285-293.
2. Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edn. (2008 revision) Br J Pharmacol 153 (Suppl 2): S1-S209.
3. Baxter GS, Clayton JK, Coleman RA, Marshall K, Sangha R, Senior J (1995). Characterization of the prostanoid receptors mediating constriction and relaxation of human isolated uterine artery. Br J Pharmacol 116: 1692-1696.
4. Bayston T, Ramessur S, Reise J, Jones KG, Powell JT (2003). Prostaglandin E2 receptors in abdominal aortic aneurysm and human aortic smooth muscle cells. J Vasc Surg 38: 354-359.
5. Billot X, Chateauneuf A, Chauret N, Denis D, Greig G, Mathieu MC et al. (2003). Discovery of a potent and selective agonist of the prostaglandin EP4 receptor. Bioorg Med Chem Lett 13: 1129-1132.
6. Boersma JI, Janzen KM, Oliveira L, Crankshaw DJ (1999). Characterization of excitatory prostanoid receptors in the human umbilical artery in vitro. Br J Pharmacol 128: 1505-1512.
7. Camacho M, Gerboles E, Escudero JR, Anton R, Garcia-Moll X, Vila L (2007). Microsomal prostaglandin E synthase-1, which is not coupled to a particular cyclooxygenase isoenzyme, is essential for prostaglandin E(2) biosynthesis in vascular smooth muscle cells. J Thromb Haemost 5: 1411-1419.
8. Campos KR, Journet M, Cai D, Kowal JJ, Lee S, Larsen RD et al. (2003). A practical synthesis for the core structure of a family of selective prostaglandin D2 receptor antagonists. J Org Chem 68: 2338-2342.
9. Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ (2001). Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 167: 2831-2838.
10. Cipollone F, Fazia ML, Iezzi A, Cuccurullo C, De Cesare D, Ucchino S, Spigonardo F, Marchetti A, Buttitta F, Paloscia L, Mascellanti M, Cuccurullo F, Mezzetti A (2005). Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. Arterioscler Thromb Vasc Biol 25: 1925-1931.
11. Clark RD, Jahangir A, Severance D, Salazar R, Chang T, Chang D et al. (2004). Discovery and SAR development of 2-(phenylamino) imidazolines as prostacyclin receptor antagonists [corrected]. Bioorg Med Chem Lett 14: 1053-1056.
12. Coleman RA, Grix SP, Head SA, Louttit JB, Mallett A, Sheldrick RL (1994). A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins 47: 151-168.
13. Davis RJ, Murdoch CE, Ali M, Purbrick S, Ravid R, Baxter GS et al. (2004). EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. Br J Pharmacol 141: 580-585.
14. Hao CM, Breyer MD (2007). Roles of lipid mediators in kidney injury. Semin Nephrol 27: 338-351.
15. Haye-Legrand I, Bourdillat B, Labat C, Cerrina J, Norel X, Benveniste J et al. (1987). Relaxation of isolated human pulmonary muscle preparations with prostacyclin (PGI2) and its analogs. Prostaglandins 33: 845-854.
16. Jones RL, Chan KM (2005). Investigation of the agonist activity of prostacyclin analogues on prostanoid EP4 receptors using GW 627368 and taprostene: evidence for species differences. Prostaglandins Leukot Essent Fatty Acids 72: 289-299.
17. Keery RJ, Lumley P (1988). AH6809, a prostaglandin DP-receptor blocking drug on human platelets. Br J Pharmacol 94: 745-754.
18. Leonhardt A, Glaser A, Wegmann M, Hackenberg R, Nusing RM (2003a). Expression of prostanoid receptors in human lower segment pregnant myometrium. Prostaglandins Leukot Essent Fatty Acids 69: 307-313.
19. Leonhardt A, Glaser A, Wegmann M, Schranz D, Seyberth H, Nusing R (2003b). Expression of prostanoid receptors in human ductus arteriosus. Br J Pharmacol 138: 655-659.
20. Maruyama T, Ohuchida S (2000). [Selective agonists and antagonists for prostaglandin E2 receptor subtypes]. Tanpakushitsu Kakusan Koso 45 (6 Suppl): 1001-1007.
21. Milne SA, Armstrong RA, Woodward DF (1995). Comparison of the EP receptor subtypes mediating relaxation of the rabbit jugular and pig saphenous veins. Prostaglandins 49: 225-237.
22. Norel X (2007). Prostanoid receptors in the human vascular wall. ScientificWorldJournal 7: 1359-1374.
23. Norel X, de Montpreville V, Brink C (2004a). Vasoconstriction induced by activation of EP1 and EP3 receptors in human lung: effects of ONO-AE-248, ONO-DI-004, ONO-8711 or ONO-8713. Prostaglandins Other Lipid Mediat 74: 101-112.
24. Norel X, Labat C, Gardiner PJ, Brink C (1991). Inhibitory effects of BAY u3405 on prostanoid-induced contractions in human isolated bronchial and pulmonary arterial muscle preparations. Br J Pharmacol 104: 591-595.
25. Norel X, Walch L, Gascard JP, deMontpreville V, Brink C (2004b). Prostacyclin release and receptor activation: differential control of human pulmonary venous and arterial tone. Br J Pharmacol 142: 788-796.
26. Norel X, Walch L, Labat C, Gascard JP, Dulmet E, Brink C (1999). Prostanoid receptors involved in the relaxation of human bronchial preparations. Br J Pharmacol 126: 867-872.
27. Okahara K, Sun B, Kambayashi J (1998). Upregulation of prostacyclin synthesis-related gene expression by shear stress in vascular endothelial cells. Arterioscler Thromb Vasc Biol 18: 1922-1926.
28. Pichiule P, Chavez JC, LaManna JC (2004). Hypoxic regulation of angiopoietin-2 expression in endothelial cells. J Biol Chem 279: 12171-12180.
29. Qian YM, Jones RL, Chan KM, Stock AI, Ho JK (1994). Potent contractile actions of prostanoid EP3-receptor agonists on human isolated pulmonary artery. Br J Pharmacol 113: 369-374.
30. Sekiguchi M, Konno S, Kikuchi S (2006). Effects on improvement of blood flow in the chronically compressed cauda equina: comparison between a selective prostaglandin E receptor (EP4) agonist and a prostaglandin E1 derivate. Spine 31: 869-872.
31. Smith GC (1998). The pharmacology of the ductus arteriosus. Pharmacol Rev 50: 35-58.
32. Smith GC, Coleman RA, McGrath JC (1994). Characterization of dilator prostanoid receptors in the fetal rabbit ductus arteriosus. J Pharmacol Exp Ther 271: 390-396.
33. Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F et al. (2000). The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 141: 1554-1559.
34. Therland KL, Stubbe J, Thiesson HC, Ottosen PD, Walter S, Sorensen GL et al. (2004). Cycloxygenase-2 is expressed in vasculature of normal and ischemic adult human kidney and is colocalized with vascular prostaglandin E2 EP4 receptors. J Am Soc Nephrol 15: 1189-1198.
35. Uracz W, Uracz D, Olszanecki R, Gryglewski RJ (2002). Interleukin 1beta induces functional prostaglandin E synthase in cultured human umbilical vein endothelial cells. J Physiol Pharmacol 53 (4 Part 1): 643-654.
36. von Scheidt W, Costard-Jaeckle A, Stempfle HU, Deng MC, Schwaab B, Haaff B et al. (2006). Prostaglandin E1 testing in heart failure-associated pulmonary hypertension enables transplantation: the PROPHET study. J Heart Lung Transplant 25: 1070-1076.
37. Walch L, de Montpreville V, Brink C, Norel X (2001). Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins. Br J Pharmacol 134: 1671-1678.
38. Walch L, Labat C, Gascard JP, de Montpreville V, Brink C, Norel X (1999). Prostanoid receptors involved in the relaxation of human pulmonary vessels. Br J Pharmacol 126: 859-866.
39. Wilson RJ, Giblin GM, Roomans S, Rhodes SA, Cartwright KA, Shield VJ et al. (2006). GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H- benzo[f]isoindol-2-yl)phenyl] acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br J Pharmacol 148: 326-339.
40. Wilson RJ, Giles H (2005). Piglet saphenous vein contains multiple relaxatory prostanoid receptors: evidence for EP4, EP2, DP and IP receptor subtypes. Br J Pharmacol 144: 405-415.
41. Wilson RJ, Rhodes SA, Wood RL, Shield VJ, Noel LS, Gray DW et al. (2004). Functional pharmacology of human prostanoid EP2 and EP4 receptors. Eur J Pharmacol 501: 49-58.
42. Wolff B, Lodziewski S, Bollmann T, Opitz CF, Ewert R (2007). Impaired peripheral endothelial function in severe idiopathic pulmonary hypertension correlates with the pulmonary vascular response to inhaled iloprost. Am Heart J 153: 1088.e1-1088.e7.
43. Yokoyama U, Minamisawa S, Quan H, Ghatak S, Akaike T, Segi-Nishida E et al. (2006). Chronic activation of the prostaglandin receptor EP4 promotes hyaluronan-mediated neointimal formation in the ductus arteriosus. J Clin Invest 116: 3026-3034.
44. Young RN, Billot X, Han YX, Slipetz DA, Chauret N, Belley M et al. (2004). Discovery and synthesis of a potent, selective and orally bioavailable EP4 receptor agonist. Heterocycles 64: 437-446.